Oraqix (Lidocaine, Prilocaine)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilizing the membrane and preventing the initiation and propagation of action potentials. This inhibition stops pain signals from reaching the brain, resulting in localized loss of sensation.

The exact amount of Oraqix applied is determined by the prescribing clinician based on the treatment area and procedure. The product is supplied in a single‑use syringe or ampoule, and the prescriber decides the appropriate volume to achieve adequate anesthesia.

Lidocaine and prilocaine are classified as Category B (US) with limited data; they should be used during pregnancy or lactation only if the anticipated benefit justifies any potential risk to the fetus or infant. Each case should be evaluated individually by the prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and necessary import documentation.

Compared with injectable lidocaine solutions, Oraqix offers a non‑invasive, surface‑only anesthesia that eliminates needle use, reducing patient anxiety. While its duration may be shorter than infiltrative blocks, it provides rapid onset and convenience for superficial dental procedures.

Oraqix should be stored at room temperature, below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture and extreme temperatures. Do not freeze; discard any product that appears discolored or has an altered consistency.

The gel is applied directly onto the targeted oral mucosa using the supplied applicator or a sterile cotton tip. The clinician spreads a thin layer over the area, allowing it to remain in place for a few minutes to achieve anesthesia before proceeding with the procedure.

Serious adverse reactions, though rare, can include allergic responses such as anaphylaxis, methemoglobinemia (especially related to prilocaine), and systemic toxicity presenting as seizures or cardiovascular depression. Immediate medical attention is required if any of these occur.

Contra‑indications include patients with known hypersensitivity to amide‑type local anesthetics, lidocaine, prilocaine, or any component of the formulation. It should also be avoided in individuals with severe cardiac conduction disorders, methemoglobinemia, or those receiving high cumulative doses of other local anesthetics.